Enhance.MD Review

What Enhance.MD charges

• Semaglutide: $249/mo — per month, "Billed every 4 weeks", the same at every dose; longer terms run $237, $224 and $212 a month
• Tirzepatide: $329/mo — per month, "Billed every 4 weeks"; longer terms run $313, $296 and $280 a month
• Tirzepatide: $189/mo — per month, "Billed every 12 weeks"; the one-month tier on this product renders no figure at all
• NAD+: $199/mo — per month, "Billed every 4 weeks"; longer terms run $189, $179 and $169 a month
• NAD+: $99/mo — per month, "Billed every 4 weeks"; longer terms run $94, $89 and $84 a month

It lists the states rather than claiming the count

Its FAQ says "Enhance.MD is licensed in all 50 states. However, based on product availability, we will be launching in select states which currently include:" and then names forty-one.

The list is what is recorded here. The fifty in the sentence before it is a licensure claim the seller itself immediately qualifies, so no fifty-state coverage is credited.

That is the right way round for a reader: an enumeration can be checked against your own state, and a count cannot.

Three pharmacies named, and labs inside the fee

It names three pharmacies outright rather than describing a class of pharmacy, which puts the dispensing chain in the open.

Metabolic lab testing every six months is listed among what the monthly price buys, and its FAQ says the programme includes comprehensive laboratory diagnostics and names where the draw happens.

Its own words on the category: "This compounded formulation is not FDA-approved and is intended solely for patients under active care of a licensed prescriber. It is compounded in accordance with federal Section 503A guidelines." Quoted, not endorsed.

A price that never renders

On the microdosing tirzepatide product, the one-month tier prints its label and the words billed every four weeks, and then no figure.

Every sibling product page prints a one-month figure in exactly that slot, so this is a fault on one page rather than a deliberate omission across the catalogue.

The three-month rate is filed here instead, and the gap is named rather than papered over. A reader who wants a single month of that product will have to ask what it costs.

Two ladders on every page, and a blend that has no price of its own

Each product page carries two price ladders: the product's own, and an NAD+ wafer add-on directly beneath it. Reading the second as the page's headline compound is the easy mistake.

The NAD+ therapy page is what disambiguates them, because there both ladders are NAD+ — the injection on one, the sublingual wafer on the other, each with its own figure.

Its Elite product combines tirzepatide and semaglutide in one preparation. A blend named for two compounds is not a price for either, so it is not filed against either.

How we verified this

• Recorded the enumerated launch list of forty-one states and declined the licensed-in-fifty sentence the seller qualifies in the same breath.
• Confirmed the microdosing product's one-month tier renders a label and a billing cycle with no figure, checked sibling pages that do render one, and filed the three-month rate instead.
• Separated the two ladders on each product page using the NAD+ therapy page, where both ladders are NAD+, rather than assuming the second belonged to the page's headline compound.
• Requested a deliberately meaningless address on this host in the same session and confirmed it returns a not-found response.
• Screened the brand under two spellings and all three named pharmacies against the live federal warning-letter table, pulling all 3,677 records in pages and filtering locally because the table's own search parameter is ignored, with a positive and a nonsense control in the same run. No letters for any of them.